Comparing Apretude vs Cabenuva
| Apretude (cabotegravir) | Cabenuva (cabotegravir / rilpivirine) |
|
|---|
| Apretude (cabotegravir) | Cabenuva (cabotegravir / rilpivirine) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV. Apretude may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for HIV Infection. Cabenuva may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Apretude (cabotegravir) | More about Cabenuva (cabotegravir / rilpivirine) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Apretude has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Cabenuva has an average rating of 7.7 out of 10 from a total of 28 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Apretude side effects |
View all Cabenuva side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Apretude prices |
View all Cabenuva prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other cabotegravir brands include: Vocabria |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
41 hours |
50 hours (empirically) |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 66 drugs are known to interact with Apretude:
|
A total of 460 drugs are known to interact with Cabenuva:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
January 21, 2021 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Sunlenca
Sunlenca (lenacapavir) is used for the treatment of HIV-1 infection in heavily ...
Vocabria
Vocabria (cabotegravir) is used in the treatment of HIV-1 infection in adults. Includes Vocabria ...
AccessPak for HIV PEP Basic
AccessPak for HIV PEP Basic is used for HIV Infection, nonoccupational exposure, occupational ...
Lenacapavir
Lenacapavir is used to treat HIV-1 infection (in combination with other antivirals) or for HIV-1 ...
Emtricitabine/tenofovir disoproxil
Emtricitabine/tenofovir disoproxil (brand name Truvada) is a combination antiviral tablet that may ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.